A groundbreaking study published in the Journal of Clinical Investigation reveals that treating type 2 diabetes may require focusing on specific brain neurons rather than solely addressing obesity or insulin resistance. The research challenges long-held assumptions about the causes of diabetes and opens new avenues for potential therapies.
Researchers from UW Medicine discovered that hyperactivity in a group of neurons called AgRP neurons, located in the hypothalamus, plays a significant role in elevated blood sugar levels in diabetic mice. By using a viral genetics approach to silence these neurons, the team unexpectedly normalized blood sugar levels for months, without affecting body weight or food intake.
Dr. Michael Schwartz, the study’s corresponding author, explained, “These neurons are playing an outsized role in hyperglycemia and type 2 diabetes.” The findings align with earlier research by the same team, which showed that injecting a peptide (FGF1) into the brain could also induce diabetes remission by inhibiting AgRP neurons.
Traditionally, type 2 diabetes has been attributed to genetic factors and lifestyle choices, such as obesity and poor diet, leading to insulin resistance. However, this study suggests the brain may be a key player in the disease.
“This is a departure from the conventional wisdom of what causes diabetes,” Schwartz said. The research indicates that while AgRP neurons influence blood sugar control, they may not significantly contribute to obesity, meaning therapies targeting these neurons could treat diabetes without necessarily reversing weight gain.
The study raises the possibility of developing treatments that regulate AgRP neuron activity to manage diabetes. Schwartz noted that drugs like Ozempic, which also inhibit these neurons, might owe part of their effectiveness to this mechanism. Further research is needed to explore how these neurons become hyperactive and how their regulation could be harnessed for human therapies.
Schwartz, a leading expert in diabetes and obesity research, emphasized the importance of translating these findings into clinical trials. The study marks a potential shift in how scientists and clinicians approach type 2 diabetes treatment.
Add comment